Advertisement

Topics

PHAROS GmbH Company Profile

01:05 EST 20th February 2018 | BioPortfolio

PHAROS GmbH is a Contract Research Organisation for Early Clinical Research and various related services. All of our services are custom designed, thus these pages are only a guide to the types of services we are able to offer.Our main services are:
Clinical Trial Services
Phase I Study Services
• Bioequivalence Study Services
• Clinical Trial Elements and Procedures
Quality Management Services
Monitoring, Audit and Quality Management Services

Location

Horvelsinger Weg 52-1
Ulm
89081
Germany

Contact

Phone: 49-731-96 46-0
Fax: 49-731-96 46-600
Email: info@pharos-gmbh.com


News Articles [121 Associated News Articles listed on BioPortfolio]

GNA Biosolutions Reveals New Ultrafast PCR Platform at Medical Trade Show

GNA Biosolutions GmbH, a molecular technology company, will showcase its new Pharos V8, the world's first laser PCR platform, at...

GNA Biosolutions Reveals New Ultrafast PCR Platform at Medica

     (Photo: http://mma.prnewswire.com/media/602187/GNA_Biosolutions.jpg) The patented technology behind the Pharos V8 platform is Laser PCR ®. Laser PCR ®operates on the same principles ...

Pharos Capital’s Family Treatment Network Acquires Behavior Care Specialists

Autism Disorder Treatment Services Add to Firm’s Behavioral Health Portfolio Pharos Capital Group, LLC (“Pharos”), through its Family Treatment Network platform (...

Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH

Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligati...

Original-Research: Medigene AG (von EQUITS GmbH): Kaufen

Original-Research: Medigene AG - von EQUITS GmbH Einstufung von EQUITS GmbH zu Medigene AG Unternehmen: Medigene AG ISIN: DE000A1X3W00 Anlass der Studie: Übernahme-Angebot Empfehlung: Kaufen Kursz...

Endocyte licenses radioligand prostate cancer therapy from ABX GMBH

Endocyte Inc. received exclusive global rights to the radioligand therapeutic PSMA617 (177LuPSMA617) from ABX GMBH.

NexWafe GmbH schließt Finanzierung in Höhe von 8 Millionen Euro ab

NexWafe GmbH, ein Spin-off des Fraunhofer ISE, das eine bahnbrechende Technologie zur epitaktischen Herstellung von Siliziumwafern für Photovoltaik kommerzialisiert, gab heute den Abschluss einer F...

Körber Plans Takeover of Systec Services GmbH

     (Photo: http://mma.prnewswire.com/media/558312/SystecServices_Headquarters.jpg) With the planned takeover, Körber Medipak Systems GmbH, the holding company of Business Area Pharma Systems...

PubMed Articles [15 Associated PubMed Articles listed on BioPortfolio]

Postoperative Corneal Asphericity in Low, Moderate, and High Myopic Eyes After Transepithelial PRK Using a New Pulse Allocation.

To evaluate the postoperative asphericity in low, moderate, and high myopic eyes after combined transepithelial photorefractive keratectomy and SmartSurfACE treatment (SCHWIND eye-tech-solutions GmbH,...

Reliability of a Skin Diagnostic Device in Assessing Hydration and Erythema.

To examine the reliability of a skin diagnostic device, the SD202 (Courage+Khazaka GmBH, Cologne, Germany), in assessing hydration and erythema of periwound skin and pressure injury-prone areas.

Scleral Thinning Documented by Ultrasound Biomicroscopy after Plaque Therapy for Anterior Ciliary Melanoma.

To evaluate, by ultrasound biomicroscopy (UBM), changes in scleral thickness after ruthenium-106 CCB and CCC plaque (Eckert & Ziegler BE-BIG GmbH, Berlin, Germany) therapy for anterior ciliary melanom...

Cyclic fatigue and torsional strength of three different thermally treated reciprocating nickel-titanium instruments.

The aim of this study was to evaluate the cyclic and torsional fatigue resistance of the reciprocating single-file systems Reciproc Blue 25.08 (VDW GmbH, Munich, Germany), Prodesign R 25.06 (Easy Dent...

DIC in Decompensated Cirrhosis caused by Prothrombin Complex Concentrate and Recombinant Activated Factor VII: A Word of Caution.

We would like to respond to Scott et al. and the accompanying editorial.(1,2) Concentrated factor products like recombinant activated factor VII (NovoSeven(®) , Novo Nordisk Pharmaceuticals Inc.) an...

Clinical Trials [40 Associated Clinical Trials listed on BioPortfolio]

VISSIT Intracranial Stent Study for Ischemic Therapy

The main objective of this study is to prospectively evaluate the safety, probable benefit, and effectiveness of the PHAROS Vitesse Neurovascular Stent System in a multicenter, randomized ...

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

User Performance Evaluation of Contour® Plus One, Accu-Chek® Performa Connect, FreeStyle Optium Neo and OneTouch® Select Plus Blood Glucose Monitoring Systems Following ISO 15197:2013; EN ISO 15197:2015

The user performance evaluation shows whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system. In this study, user performance e...

Telemedical Examination of a Three-Component Oculomotor Testing Battery

The study investigates the feasibility and safety of the telemedical implementation of three diagnostic oculomotor tests using a video-oculography device and an extended teleconferencing s...

Companies [530 Associated Companies listed on BioPortfolio]

PHAROS GmbH

PHAROS GmbH is a Contract Research Organisation for Early Clinical Research and various related services. All of our services are custom designed, thus these pages are only a guide to the types of ser...

Pharos Capital Group, LLC

Based in Dallas and Nashville, Pharos (www.pharosfunds.com) primarily invests $10 to $30 million in companies seeking later stage equity funding for internal growth, acquisitions,...

Pharos Innovations

Founded in 1995, Pharos Innovations assists healthcare providers and payers in achieving next generation clinical and financial performance improvement. An innovative, device-free platform, Tel-Assura...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH, located in Berlin (Germany) is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control ...

More Information about "PHAROS GmbH" on BioPortfolio

We have published hundreds of PHAROS GmbH news stories on BioPortfolio along with dozens of PHAROS GmbH Clinical Trials and PubMed Articles about PHAROS GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PHAROS GmbH Companies in our database. You can also find out about relevant PHAROS GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record